BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Churchyard GJ, Chaisson RE, Maartens G, Getahun H. Tuberculosis preventive therapy: an underutilised strategy to reduce individual risk of TB and contribute to TB control. S Afr Med J. 2014;104:339-343. [PMID: 25212199 DOI: 10.7196/samj.8290] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
Number Citing Articles
1 Russom M, Jeannetot DYB, Tesfamariam S, Stricker BH, Verhamme K. Perspectives of Healthcare Professionals on Factors Limiting Implementation of Isoniazid Preventive Therapy in People Living with HIV in Eritrea: A Qualitative Study. Risk Manag Healthc Policy 2022;15:1407-19. [PMID: 35911087 DOI: 10.2147/RMHP.S368315] [Reference Citation Analysis]
2 Williams H, Ehrlich R, Barker S, Kisting-Cairncross S, Zungu M, Yassi A. The Utility of Length of Mining Service and Latency in Predicting Silicosis among Claimants to a Compensation Trust. Int J Environ Res Public Health 2022;19:3562. [PMID: 35329249 DOI: 10.3390/ijerph19063562] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 van de Water BJ, Meyer TN, Wilson M, Young C, Gaunt B, le Roux KW. TB prevention cascade at a district hospital in rural Eastern Cape, South Africa. Public Health Action 2021;11:97-100. [PMID: 34159070 DOI: 10.5588/pha.20.0055] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Salehi M, Vahabi N, Pirhoseini H, Zayeri F. Trend analysis and longitudinal clustering of tuberculosis mortality in Asian and North African countries: Results from the global burden of disease 2017 study. Med J Islam Repub Iran 2021;35:46. [PMID: 34268234 DOI: 10.47176/mjiri.35.46] [Reference Citation Analysis]
5 Adeniyi OV, Selanto-Chairman N, Owolabi EO, Ajayi AI, Kayembe DK, Ter Goon D, Gordana A, Lambert J. Inequality in uptake of isoniazid prevention therapy and Mantoux test among pregnant women with HIV in the Eastern Cape, South Africa. BMC Public Health 2019;19:1407. [PMID: 31664978 DOI: 10.1186/s12889-019-7769-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
6 Adams S, Ehrlich R, Baatjies R, Dendukuri N, Wang Z, Dheda K. Evaluating Latent Tuberculosis Infection Test Performance Using Latent Class Analysis in a TB and HIV Endemic Setting. Int J Environ Res Public Health 2019;16:E2912. [PMID: 31416206 DOI: 10.3390/ijerph16162912] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
7 Sumner T, Scriba TJ, Penn-Nicholson A, Hatherill M, White RG. Potential population level impact on tuberculosis incidence of using an mRNA expression signature correlate-of-risk test to target tuberculosis preventive therapy. Sci Rep 2019;9:11126. [PMID: 31366947 DOI: 10.1038/s41598-019-47645-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
8 Boffa J, Mayan M, Ndlovu S, Fisher D, Staples S, Sauve R, Williamson T. When prevention is dangerous: perceptions of isoniazid preventive therapy in KwaZulu-Natal, South Africa. Public Health Action 2019;9:24-31. [PMID: 30963039 DOI: 10.5588/pha.18.0040] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
9 Van Ginderdeuren E, Bassett J, Hanrahan C, Mutunga L, Van Rie A. Health system barriers to implementation of TB preventive strategies in South African primary care facilities. PLoS One 2019;14:e0212035. [PMID: 30763378 DOI: 10.1371/journal.pone.0212035] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
10 Kunkel A, Colijn C, Lipsitch M, Cohen T. How could preventive therapy affect the prevalence of drug resistance? Causes and consequences. Philos Trans R Soc Lond B Biol Sci 2015;370:20140306. [PMID: 25918446 DOI: 10.1098/rstb.2014.0306] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
11 Akolo C, Bada F, Okpokoro E, Nwanne O, Iziduh S, Usoroh E, Ali T, Ibeziako V, Oladimeji O, Odo M. Debunking the myths perpetuating low implementation of isoniazid preventive therapy amongst human immunodeficiency virus-infected persons. World J Virology 2015; 4(2): 105-112 [PMID: 25964875 DOI: 10.5501/wjv.v4.i2.105] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
12 Kizza FN, List J, Nkwata AK, Okwera A, Ezeamama AE, Whalen CC, Sekandi JN. Prevalence of latent tuberculosis infection and associated risk factors in an urban African setting. BMC Infect Dis 2015;15:165. [PMID: 25879423 DOI: 10.1186/s12879-015-0904-1] [Cited by in Crossref: 26] [Cited by in F6Publishing: 31] [Article Influence: 3.7] [Reference Citation Analysis]
13 Fielding KL, Charalambous S, Hoffmann CJ, Johnson S, Tlali M, Dorman SE, Vassall A, Churchyard GJ, Grant AD. Evaluation of a point-of-care tuberculosis test-and-treat algorithm on early mortality in people with HIV accessing antiretroviral therapy (TB Fast Track study): study protocol for a cluster randomised controlled trial. Trials 2015;16:125. [PMID: 25872501 DOI: 10.1186/s13063-015-0650-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]